{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:36:12Z","timestamp":1790760972324,"version":"4.1.0"},"reference-count":290,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG23179 and IG15378"],"award-info":[{"award-number":["IG23179 and IG15378"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has significantly improved the survival of MM patients. Notably, all these responses are highly dependent on the fitness of the host immune system, including the innate compartment. Among immune cells involved in cancer immunity, properly activated plasmacytoid dendritic cells (pDCs) exert an important role, bridging the innate and adaptive immune responses and directly eliminating cancer cells. A distinctive feature of pDCs is the production of high amount of type I Interferon (I-IFN), through the Toll-like receptor (TLR) 7 and 9 signaling pathway activation. However, published data indicate that melanoma-associated escape mechanisms are in place to hijack pDC functions. We have recently reported that pDC recruitment is recurrent in the early phases of melanoma, but the entire pDC compartment collapses over melanoma progression. Here, we summarize recent advances on pDC biology and function within the context of melanoma immunity.<\/jats:p>","DOI":"10.3390\/cells9020417","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:45:30Z","timestamp":1581421530000},"page":"417","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma"],"prefix":"10.3390","volume":"9","author":[{"given":"Matilde","family":"Monti","sequence":"first","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-8334","authenticated-orcid":false,"given":"Francesca","family":"Consoli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia at ASST-Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Vescovi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bugatti","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-2997","authenticated-orcid":false,"given":"William","family":"Vermi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"},{"name":"Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Li, S., Wu, J., Zhu, S., Liu, Y.J., and Chen, J. (2017). Disease-Associated Plasmacytoid Dendritic Cells. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01268"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.0105-2896.2009.00881.x","article-title":"Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance","volume":"234","author":"Swiecki","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.4049\/jimmunol.1401541","article-title":"The plasmacytoid dendritic cell as the Swiss army knife of the immune system: Molecular regulation of its multifaceted functions","volume":"193","author":"Karrich","year":"2014","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13238-012-2104-8","article-title":"Regulation of TLR7\/9 signaling in plasmacytoid dendritic cells","volume":"4","author":"Bao","year":"2013","journal-title":"Protein Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.immuni.2008.09.002","article-title":"Antigen-presentation properties of plasmacytoid dendritic cells","volume":"29","author":"Villadangos","year":"2008","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3389\/fimmu.2019.01222","article-title":"What Makes a pDC: Recent Advances in Understanding Plasmacytoid DC Development and Heterogeneity","volume":"10","author":"Musumeci","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.it.2010.05.004","article-title":"Trafficking properties of plasmacytoid dendritic cells in health and disease","volume":"31","author":"Sozzani","year":"2010","journal-title":"Trends Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1189\/jlb.0411190","article-title":"Plasmacytoid dendritic cells and cancer","volume":"90","author":"Vermi","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Koucky, V., Boucek, J., and Fialova, A. (2019). Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review. Cancers (Basel), 11.","DOI":"10.3390\/cancers11040470"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000205419","article-title":"Karyometric research on lymph node cells in man. I. Germinoblasts, lymphoblasts & lymphocytes","volume":"19","author":"Lennert","year":"1958","journal-title":"Acta Haematol."},{"key":"ref_13","first-page":"15","article-title":"Plasmacytoid T cells. Immunohistochemical evidence for their monocyte\/macrophage origin","volume":"133","author":"Facchetti","year":"1988","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-003-0918-8","article-title":"The plasmacytoid monocyte\/interferon producing cells","volume":"443","author":"Facchetti","year":"2003","journal-title":"Virchows Arch."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1344","article-title":"Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas","volume":"200","author":"Vermi","year":"2003","journal-title":"J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type 1 interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/11360","article-title":"Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon","volume":"5","author":"Cella","year":"1999","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0198-8859(02)00752-8","article-title":"Plasmacytoid dendritic cells: From specific surface markers to specific cellular functions","volume":"63","author":"Dzionek","year":"2002","journal-title":"Hum. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1365-2559.1999.0728d.x","article-title":"Plasmacytoid monocytes express IL3-receptor alpha and differentiate into dendritic cells","volume":"35","author":"Facchetti","year":"1999","journal-title":"Histopathology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.exphem.2012.01.002","article-title":"Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34(+) hematopoietic progenitor cells: Use of interleukin-3","volume":"40","author":"Demoulin","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.4049\/jimmunol.165.11.6037","article-title":"BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood","volume":"165","author":"Dzionek","year":"2000","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.4049\/jimmunol.0802008","article-title":"CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions","volume":"182","author":"Matsui","year":"2009","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1073\/pnas.1610630114","article-title":"A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41590-017-0012-z","article-title":"Diversification of human plasmacytoid predendritic cells in response to a single stimulus","volume":"19","author":"Alculumbre","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1038\/s41467-018-05784-3","article-title":"Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells","volume":"9","author":"Wimmers","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/imcb.12173","article-title":"Plasmacytoid dendritic cell heterogeneity is defined by CXCL10 expression following TLR7 stimulation","volume":"96","author":"Marsman","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.V96.3.878","article-title":"In vivo generation of human dendritic cell subsets by Flt3 ligand","volume":"96","author":"Maraskovsky","year":"2000","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.20030323","article-title":"Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo","volume":"198","author":"Karsunky","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.20030107","article-title":"The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3","volume":"198","author":"Wu","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1084\/jem.20141442","article-title":"Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow","volume":"212","author":"Lee","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.celrep.2017.06.075","article-title":"Dendritic Cell Lineage Potential in Human Early Hematopoietic Progenitors","volume":"20","author":"Helft","year":"2017","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.4049\/jimmunol.175.11.7281","article-title":"Plasmacytoid dendritic cells of different origins have distinct characteristics and function: Studies of lymphoid progenitors versus myeloid progenitors","volume":"175","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2008.09.016","article-title":"Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development","volume":"135","author":"Cisse","year":"2008","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2010.05.005","article-title":"The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner","volume":"32","author":"Carotta","year":"2010","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.20021263","article-title":"ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells","volume":"196","author":"Schiavoni","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20041231","article-title":"The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development","volume":"200","author":"Schotte","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1084\/jem.20130536","article-title":"A type I IFN-Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors","volume":"210","author":"Chen","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.immuni.2010.11.023","article-title":"Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells","volume":"33","author":"Ghosh","year":"2010","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2011-07-370239","article-title":"The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1","volume":"119","author":"Karrich","year":"2012","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1074-7613(03)00332-7","article-title":"STAT3 is required for Flt3L-dependent dendritic cell differentiation","volume":"19","author":"Laouar","year":"2003","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.immuni.2008.02.013","article-title":"The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8","volume":"28","author":"Esashi","year":"2008","journal-title":"Immunity"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2012-07-441311","article-title":"The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature12013","article-title":"Diverse and heritable lineage imprinting of early haematopoietic progenitors","volume":"496","author":"Naik","year":"2013","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1084\/jem.20041310","article-title":"Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin","volume":"201","author":"Vermi","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.4049\/jimmunol.169.11.6079","article-title":"IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation","volume":"169","author":"Krug","year":"2002","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4049\/jimmunol.1002598","article-title":"CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions","volume":"186","author":"Seth","year":"2011","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.1200802","article-title":"Constitutive plasmacytoid dendritic cell migration to the splenic white pulp is cooperatively regulated by CCR7- and CXCR4-mediated signaling","volume":"189","author":"Umemoto","year":"2012","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.192.2.219","article-title":"Natural interferon alpha\/beta-producing cells link innate and adaptive immunity","volume":"192","author":"Kadowaki","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1994.1504","article-title":"Viral induction of low frequency interferon-alpha producing cells","volume":"204","author":"Feldman","year":"1994","journal-title":"Virology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2005-07-2709","article-title":"Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells","volume":"107","author":"Ito","year":"2006","journal-title":"Blood"},{"key":"ref_51","first-page":"S16","article-title":"Natural interferon-alpha producing cells: The plasmacytoid dendritic cells","volume":"33","year":"2002","journal-title":"Biotechniques"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.immuni.2007.06.009","article-title":"The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8","volume":"27","author":"Tailor","year":"2007","journal-title":"Immunity"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1084\/jem.20110654","article-title":"Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo","volume":"208","author":"Swiecki","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1126\/science.1136880","article-title":"Autophagy-dependent viral recognition by plasmacytoid dendritic cells","volume":"315","author":"Lee","year":"2007","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.4049\/jimmunol.171.6.3296","article-title":"Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG","volume":"171","author":"Bave","year":"2003","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.4049\/jimmunol.178.6.3363","article-title":"Cutting Edge: Antibody-mediated TLR7-dependent recognition of viral RNA","volume":"178","author":"Wang","year":"2007","journal-title":"J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15416","DOI":"10.1073\/pnas.0406933101","article-title":"Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling","volume":"101","author":"Honda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nature03547","article-title":"Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.20060401","article-title":"Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation","volume":"203","author":"Guiducci","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41586-019-1611-7","article-title":"Release from UNC93B1 reinforces the compartmentalized activation of select TLRs","volume":"575","author":"Majer","year":"2019","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-019-1612-6","article-title":"UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity","volume":"575","author":"Majer","year":"2019","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.194.12.1823","article-title":"BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha\/beta induction","volume":"194","author":"Dzionek","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cao, W., Zhang, L., Rosen, D.B., Bover, L., Watanabe, G., Bao, M., Lanier, L.L., and Liu, Y.J. (2007). BDCA2\/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol., 5.","DOI":"10.1371\/journal.pbio.0050248"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"35329","DOI":"10.1074\/jbc.C111.290494","article-title":"Human C-type lectin domain family 4, member C (CLEC4C\/BDCA-2\/CD303) is a receptor for asialo-galactosyl-oligosaccharides","volume":"286","author":"Riboldi","year":"2011","journal-title":"J. Biol Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.20052454","article-title":"Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production","volume":"203","author":"Cao","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.20090547","article-title":"Regulation of TLR7\/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction","volume":"206","author":"Cao","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2004-12-4802","article-title":"Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44","volume":"106","author":"Fuchs","year":"2005","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","article-title":"Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44","volume":"187","author":"Rosental","year":"2011","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2013.11.007","article-title":"DCIR interacts with ligands from both endogenous and pathogenic origin","volume":"158","author":"Bloem","year":"2014","journal-title":"Immunol. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2007-03-081398","article-title":"Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production","volume":"111","author":"Tacken","year":"2008","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/icb.2014.38","article-title":"TLR ligands upregulate RIG-I expression in human plasmacytoid dendritic cells in a type I IFN-independent manner","volume":"92","author":"Szabo","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","article-title":"Immune signaling by RIG-I-like receptors","volume":"34","author":"Loo","year":"2011","journal-title":"Immunity"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3389\/fimmu.2018.02314","article-title":"Regulatory NLRs Control the RLR-Mediated Type I Interferon and Inflammatory Responses in Human Dendritic Cells","volume":"9","author":"Fekete","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.201546113","article-title":"Human plasmacytoid dentritic cells elicit a Type I Interferon response by sensing DNA via the cGAS-STING signaling pathway","volume":"46","author":"Bode","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molcel.2014.03.040","article-title":"The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling","volume":"54","author":"Cai","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.immuni.2016.10.001","article-title":"Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality","volume":"45","author":"Yu","year":"2016","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Muchmore","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-019-0182-z","article-title":"Interferon-lambda orchestrates innate and adaptive mucosal immune responses","volume":"19","author":"Ye","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2217\/imt-2015-0021","article-title":"IFN-lambda cancer immunotherapy: New kid on the block","volume":"8","author":"Lasfar","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN-lambda in murine tumor models","volume":"176","author":"Sato","year":"2006","journal-title":"J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000370113","article-title":"Investigations of interferon-lambda for the treatment of cancer","volume":"7","author":"Stiff","year":"2015","journal-title":"J. Innate Immun"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/eji.200324610","article-title":"Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells","volume":"34","author":"Coccia","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1102038","article-title":"Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells","volume":"189","author":"Yin","year":"2012","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1189\/jlb.3VMA0415-144R","article-title":"Endogenously produced TNF-alpha contributes to the expression of CXCL10\/IP-10 in IFN-lambda3-activated plasmacytoid dendritic cells","volume":"99","author":"Finotti","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1189\/jlb.0509347","article-title":"Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29)","volume":"86","author":"Megjugorac","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3389\/fimmu.2017.01015","article-title":"Interferon-lambdas and Plasmacytoid Dendritic Cells: A Close Relationship","volume":"8","author":"Finotti","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4049\/jimmunol.176.1.248","article-title":"Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells","volume":"176","author":"Chaperot","year":"2006","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.exphem.2006.08.002","article-title":"Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells","volume":"34","author":"Blum","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/eji.201242385","article-title":"The transcriptional regulator NAB2 reveals a two-step induction of TRAIL in activated plasmacytoid DCs","volume":"42","author":"Balzarolo","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1172\/JCI61034","article-title":"Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells","volume":"122","author":"Drobits","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.4049\/jimmunol.1102437","article-title":"TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: Mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity","volume":"188","author":"Kalb","year":"2012","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2002-02-0638","article-title":"Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells","volume":"100","author":"Rissoan","year":"2002","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jid.2017.03.016","article-title":"IL-21 May Promote Granzyme B-Dependent NK\/Plasmacytoid Dendritic Cell Functional Interaction in Cutaneous Lupus Erythematosus","volume":"137","author":"Salvi","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/00000478-200311000-00015","article-title":"Neoplasms derived from plasmacytoid monocytes\/interferon-producing cells: Variability of CD56 and granzyme B expression","volume":"27","author":"Facchetti","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13238-015-0140-x","article-title":"Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset","volume":"6","author":"Yu","year":"2015","journal-title":"Protein Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.iy.09.040191.001415","article-title":"The dendritic cell system and its role in immunogenicity","volume":"9","author":"Steinman","year":"1991","journal-title":"Annu. Rev. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ni.1665","article-title":"Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells","volume":"9","author":"Young","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.immuni.2007.07.021","article-title":"Antigen crosspresentation by human plasmacytoid dendritic cells","volume":"27","author":"Hoeffel","year":"2007","journal-title":"Immunity"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.1602","article-title":"Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I","volume":"9","author":"Chatterjee","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2012-06-435644","article-title":"Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets","volume":"121","author":"Tel","year":"2013","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/eji.200636026","article-title":"From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre-dendritic cell differentiation","volume":"36","author":"Soumelis","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4049\/jimmunol.1000454","article-title":"Plasmacytoid dendritic cell dichotomy: Identification of IFN-alpha producing cells as a phenotypically and functionally distinct subset","volume":"186","author":"Bjorck","year":"2011","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.4049\/jimmunol.181.8.5219","article-title":"Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II","volume":"181","author":"Tacken","year":"2008","journal-title":"J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.20061660","article-title":"Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand","volume":"204","author":"Ito","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1084\/jem.20011603","article-title":"Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells","volume":"195","author":"Gilliet","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ni1333","article-title":"Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts","volume":"7","author":"Ochando","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fimmu.2013.00059","article-title":"Tolerogenic and activatory plasmacytoid dendritic cells in autoimmunity","volume":"4","author":"Guery","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Araujo, E.F., Medeiros, D.H., Galdino, N.A., Condino-Neto, A., Calich, V.L., and Loures, F.V. (2016). Tolerogenic Plasmacytoid Dendritic Cells Control Paracoccidioides brasiliensis Infection by Inducting Regulatory T Cells in an IDO-Dependent Manner. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1006115"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2008.12.017","article-title":"NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner","volume":"30","author":"Diana","year":"2009","journal-title":"Immunity"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.4049\/jimmunol.172.7.4253","article-title":"Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs","volume":"172","author":"Ito","year":"2004","journal-title":"J. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1084\/jem.20101692","article-title":"Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay","volume":"208","author":"Diana","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2009-07-235382","article-title":"Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion","volume":"115","author":"Jahrsdorfer","year":"2010","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_121","first-page":"1165","article-title":"Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice","volume":"118","author":"Liu","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.177.5.3260","article-title":"Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation","volume":"177","author":"Blasius","year":"2006","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/1521-4141(200201)32:1<97::AID-IMMU97>3.0.CO;2-Y","article-title":"Ly6C expression differentiates plasma cells from other B cell subsets in mice","volume":"32","author":"Wrammert","year":"2002","journal-title":"Eur J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.oraloncology.2019.07.019","article-title":"pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma","volume":"96","author":"Yang","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1074-7613(02)00365-5","article-title":"In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens","volume":"17","author":"Jung","year":"2002","journal-title":"Immunity"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2010.11.020","article-title":"Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual","volume":"33","author":"Swiecki","year":"2010","journal-title":"Immunity"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Mandl, M., Drechsler, M., Jansen, Y., Neideck, C., Noels, H., Faussner, A., Soehnlein, O., Weber, C., and Doring, Y. (2015). Evaluation of the BDCA2-DTR Transgenic Mouse Model in Chronic and Acute Inflammation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134176"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/JLB.3AB0119-014RR","article-title":"Plasmacytoid dendritic cell depletion modifies FoxP3+ T cell homeostasis and the clinical course of bacterial pneumonia in mice","volume":"106","author":"Lippitsch","year":"2019","journal-title":"J. Leukocyte Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20132620","article-title":"Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model","volume":"211","author":"Rowland","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1201-1339","article-title":"Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells","volume":"7","author":"Zou","year":"2001","journal-title":"Nat. Med."},{"key":"ref_131","first-page":"3019","article-title":"Effect of head and neck cancer supernatant and CpG-oligonucleotides on migration and IFN-alpha production of plasmacytoid dendritic cells","volume":"29","author":"Thiel","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.4049\/jimmunol.167.4.1862","article-title":"Cutting edge: Selective usage of chemokine receptors by plasmacytoid dendritic cells","volume":"167","author":"Penna","year":"2001","journal-title":"J. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.20020437","article-title":"The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)\/CXCL12","volume":"198","author":"Vanbervliet","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/1078-0432.CCR-04-0684","article-title":"Dendritic cell infiltration and prognosis of early stage breast cancer","volume":"10","author":"Treilleux","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10549-019-05129-8","article-title":"Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4\/SDF-1 axis","volume":"174","author":"Gadalla","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00428-011-1145-3","article-title":"Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells","volume":"459","author":"Mansfield","year":"2011","journal-title":"Virchows Arch."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/0008-5472.CAN-11-0367","article-title":"Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer","volume":"71","author":"Sisirak","year":"2011","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/0008-5472.CAN-12-2271","article-title":"Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells","volume":"72","author":"Conrad","year":"2012","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1158\/0008-5472.CAN-04-1272","article-title":"Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer","volume":"64","author":"Curiel","year":"2004","journal-title":"Cancer Res."},{"key":"ref_140","first-page":"6478","article-title":"Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer","volume":"63","author":"Hartmann","year":"2003","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.archoralbio.2017.02.012","article-title":"Increased tumor-infiltrating plasmacytoid dendritic cells predicts poor prognosis in oral squamous cell carcinoma","volume":"78","author":"Han","year":"2017","journal-title":"Arch. Oral Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.archoralbio.2018.06.006","article-title":"Culture supernatants of oral cancer cells induce impaired IFN-alpha production of pDCs partly through the down-regulation of TLR-9 expression","volume":"93","author":"Han","year":"2018","journal-title":"Arch. Oral Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.prp.2013.08.011","article-title":"Potential role of plasmacytoid dendritic cells for FOXP3+ regulatory T cell development in human colorectal cancer and tumor draining lymph node","volume":"209","author":"Gai","year":"2013","journal-title":"Pathol. Res. Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s13277-013-1297-7","article-title":"Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma","volume":"35","author":"Shi","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cei.13219","article-title":"Blood immune cell biomarkers in lung cancer","volume":"195","author":"Riemann","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4081\/aiua.2013.4.157","article-title":"Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy","volume":"85","author":"Rossi","year":"2013","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12253-013-9691-4","article-title":"Quantification of blood dendritic cells in colorectal cancer patients during the course of disease","volume":"20","author":"Orsini","year":"2014","journal-title":"Pathol. Oncol. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12967-016-0905-x","article-title":"Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer","volume":"14","author":"Gueckel","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00262-005-0697-y","article-title":"Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck","volume":"55","author":"Sakakura","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/0008-5472.CAN-12-2409","article-title":"ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells","volume":"72","author":"Faget","year":"2012","journal-title":"Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4161\/onci.18801","article-title":"Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis","volume":"1","author":"Treilleux","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e23185","DOI":"10.4161\/onci.23185","article-title":"ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells","volume":"2","author":"Faget","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e22983","DOI":"10.4161\/onci.22983","article-title":"Role of plasmacytoid dendritic cells in breast cancer bone dissemination","volume":"2","author":"Sawant","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Sisirak","year":"2012","journal-title":"Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Tjomsland, V., Sandstrom, P., Spangeus, A., Messmer, D., Emilsson, J., Falkmer, U., Falkmer, S., Magnusson, K.E., Borch, K., and Larsson, M. (2010). Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: An indicator of disease severity?. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-87"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e1008355","DOI":"10.1080\/2162402X.2015.1008355","article-title":"Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors","volume":"4","author":"Zhou","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2326-6066.CIR-13-0114-T","article-title":"Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL","volume":"1","author":"Aspord","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.178.5.2763","article-title":"Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage","volume":"178","author":"Perrot","year":"2007","journal-title":"J. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1158\/1078-0432.CCR-04-0872","article-title":"Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets","volume":"10","author":"Beckebaum","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.0902028","article-title":"Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement","volume":"184","author":"Fabricius","year":"2010","journal-title":"J. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2567.2009.03134.x","article-title":"Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha","volume":"128","author":"Schafer","year":"2009","journal-title":"Immunology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.4049\/jimmunol.175.9.5724","article-title":"TLR9- and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression","volume":"175","author":"Schroeder","year":"2005","journal-title":"J. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.4049\/jimmunol.177.9.5920","article-title":"Human plasmacytoid dendritic cell function: Inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide","volume":"177","author":"Fabricius","year":"2006","journal-title":"J. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"17259","DOI":"10.1074\/jbc.M700075200","article-title":"The Wnt5A\/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition","volume":"282","author":"Dissanayake","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2230.2012.04362.x","article-title":"Wnt5a inhibits the CpG oligodeoxynucleotide-triggered activation of human plasmacytoid dendritic cells","volume":"37","author":"Hack","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.29389","article-title":"HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells","volume":"137","author":"Demoulin","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: Receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Cao","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1158\/1078-0432.CCR-09-0171","article-title":"Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells","volume":"15","author":"Tsukamoto","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.05.008","article-title":"Plasmacytoid dendritic cell role in cutaneous malignancies","volume":"83","author":"Saadeh","year":"2016","journal-title":"J. Dermatol Sci."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Cai, D., Cao, J., Li, Z., Zheng, X., Yao, Y., Li, W., and Yuan, Z. (2009). Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-102"},{"key":"ref_173","first-page":"3985","article-title":"IL-10 in the microenvironment of HNSCC inhibits the CpG ODN induced IFN-alpha secretion of pDCs","volume":"15","author":"Bruchhage","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ijc.28072","article-title":"Breast cancer-derived transforming growth factor-beta and tumor necrosis factor-alpha compromise interferon-alpha production by tumor-associated plasmacytoid dendritic cells","volume":"133","author":"Sisirak","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/138920007780362581","article-title":"Tryptophan catabolism in IDO+ plasmacytoid dendritic cells","volume":"8","author":"Fallarino","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e22338","DOI":"10.4161\/onci.22338","article-title":"Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients","volume":"2","author":"Sisirak","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-04-4043","article-title":"Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma","volume":"65","author":"Wei","year":"2005","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood-2006-07-034785","article-title":"HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells","volume":"109","author":"Boasso","year":"2007","journal-title":"Blood"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/jid.2009.307","article-title":"Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes","volume":"130","author":"Gerlini","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.4049\/jimmunol.181.8.5396","article-title":"The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation","volume":"181","author":"Chen","year":"2008","journal-title":"J. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.ajpath.2015.07.009","article-title":"Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1alpha in an AIM2 inflammasome-dependent manner","volume":"185","author":"Sorrentino","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2014.12.047","article-title":"The role of IL-21 in immunity and cancer","volume":"358","author":"Davis","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-12-3058","article-title":"Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment","volume":"73","author":"Poujol","year":"2013","journal-title":"Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.4049\/jimmunol.178.3.1534","article-title":"Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses","volume":"178","author":"Lou","year":"2007","journal-title":"J. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons alpha and beta in cancer: Therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"11708","DOI":"10.18632\/oncotarget.14315","article-title":"TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1084\/jem.20070021","article-title":"Tumoricidal activity of TLR7\/8-activated inflammatory dendritic cells","volume":"204","author":"Stary","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1479-5876-7-86","article-title":"Main roads to melanoma","volume":"7","author":"Palmieri","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/gm175","article-title":"Environmental exposures and mutational patterns of cancer genomes","volume":"2","author":"Pfeifer","year":"2010","journal-title":"Genome Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijc.1298","article-title":"Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens","volume":"93","author":"Linnebacher","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.2174\/138161205774414556","article-title":"Direct evidence on the immune-mediated spontaneous regression of human cancer: An incentive for pharmaceutical companies to develop a novel anti-cancer vaccine","volume":"11","author":"Saleh","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1038\/srep07857","article-title":"Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma","volume":"5","author":"Guan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12166","article-title":"Shaping the repertoire of tumor-infiltrating effector and regulatory T cells","volume":"259","author":"Savage","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/CMR.0000000000000515","article-title":"Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status","volume":"29","author":"Dabrosin","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/2326-6066.CIR-18-0141","article-title":"Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome","volume":"7","author":"Vescovi","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: The impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CCO.0000000000000405","article-title":"Systemic therapy in advanced melanoma: Integrating targeted therapy and immunotherapy into clinical practice","volume":"29","author":"Silva","year":"2017","journal-title":"Curr. Opin. Oncol"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V., Del Marmol, V., Dreno, B., and Fargnoli, M.C. (2019). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. Eur. J. Cancer.","DOI":"10.1016\/j.ejca.2019.11.015"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: New rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: A pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-18-0720","article-title":"Genomic Features of Exceptional Response in Vemurafenib +\/- Cobimetinib-treated Patients with BRAF (V600)-mutated Metastatic Melanoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"10275","DOI":"10.1073\/pnas.0805459105","article-title":"Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek","volume":"105","author":"Freeman","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-018-0250-0","article-title":"Is earlier better for melanoma checkpoint blockade?","volume":"24","author":"Robert","year":"2018","journal-title":"Nat. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: A single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/labinvest.2016.132","article-title":"Immunomodulating property of MAPK inhibitors: From translational knowledge to clinical implementation","volume":"97","author":"Mandala","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00262-012-1389-z","article-title":"Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties","volume":"62","author":"Ott","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/2326-6066.CIR-15-0030","article-title":"BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma","volume":"3","author":"Bradley","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OTT.S39096","article-title":"BRAF-mutant melanoma: Treatment approaches, resistance mechanisms, and diagnostic strategies","volume":"8","author":"Spagnolo","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20160855","article-title":"An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition","volume":"214","author":"Young","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_255","first-page":"279ra241","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Mok","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1541-7786.MCR-06-0077","article-title":"Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression","volume":"4","author":"Kono","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0181","article-title":"MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells","volume":"2","author":"Vella","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1158\/1078-0432.CCR-15-0363","article-title":"Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy","volume":"21","author":"Cooper","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/eji.200323676","article-title":"Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions","volume":"33","author":"Salio","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/jid.2010.24","article-title":"Characterization of circulating dendritic cells in melanoma: Role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor","volume":"130","author":"Charles","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2007.07.018","article-title":"Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes","volume":"125","author":"Gerlini","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/2326-6066.CIR-17-0110","article-title":"Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence","volume":"5","author":"Koster","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.26511","article-title":"Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma","volume":"118","author":"Jensen","year":"2012","journal-title":"Cancer"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-014-0376-x","article-title":"Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma","volume":"13","author":"Chevolet","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2013.05.013","article-title":"Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma","volume":"337","author":"Failli","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1309\/4EJ9KL7CGDENVVLE","article-title":"Type I interferon-associated recruitment of cytotoxic lymphocytes: A common mechanism in regressive melanocytic lesions","volume":"124","author":"Wenzel","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1245\/s10434-007-9488-3","article-title":"Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients","volume":"14","author":"McCarter","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-05-500413","article-title":"BDCA-2 (CD303): A highly specific marker for normal and neoplastic plasmacytoid dendritic cells","volume":"122","author":"Boiocchi","year":"2013","journal-title":"Blood"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/jid.2014.29","article-title":"Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: Involvement of LAG-3","volume":"134","author":"Camisaschi","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_273","first-page":"970315","article-title":"Human interferon alpha-2b: A therapeutic protein for cancer treatment","volume":"2014","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/CMR.0000000000000171","article-title":"Systemic immune changes associated with adjuvant interferon-alpha2b-therapy in stage III melanoma patients: Failure at the effector phase?","volume":"25","author":"Chevolet","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CJI.0b013e31820d2a05","article-title":"Antitumor activity mediated by CpG: The route of administration is critical","volume":"34","author":"Lou","year":"2011","journal-title":"J. Immunother."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"235ra261","DOI":"10.1126\/scitranslmed.3007909","article-title":"CpG ODN nanorings induce IFNalpha from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity","volume":"6","author":"Gungor","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: A phase 1\/2 study","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/2159-8290.CD-ND2018-004","article-title":"Warming \u201cCold\u201d Melanoma with TLR9 Agonists","volume":"8","author":"Kneme","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1200\/JCO.2006.07.9129","article-title":"Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma","volume":"24","author":"Pashenkov","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CJI.0b013e318174a4df","article-title":"Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma","volume":"31","author":"Hofmann","year":"2008","journal-title":"J. Immunother."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/jid.2014.194","article-title":"Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization","volume":"134","author":"Aspord","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"e1419113","DOI":"10.1080\/2162402X.2017.1419113","article-title":"Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial","volume":"7","author":"Teulings","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_285","first-page":"9","article-title":"The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand","volume":"4","author":"Shackleton","year":"2004","journal-title":"Cancer Immun."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"Adams","year":"2008","journal-title":"J. Immunol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res."},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Aspord, C., Charles, J., Leccia, M.T., Laurin, D., Richard, M.J., Chaperot, L., and Plumas, J. (2010). A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010458"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/jid.2012.152","article-title":"HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients","volume":"132","author":"Aspord","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/2\/417\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:56:56Z","timestamp":1760173016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/2\/417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":290,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cells9020417"],"URL":"https:\/\/doi.org\/10.3390\/cells9020417","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}